Literature DB >> 9574901

Persistent parvovirus B19 infections in immunocompromised children.

G Flunker1, A Peters, S Wiersbitzky, S Modrow, W Seidel.   

Abstract

Immunocompromised patients have been shown to suffer from prolonged viral infections often without detectable immune response. Here chronic infections with low virus levels can be frequently observed. In these patients viral DNA can be detected over long periods by polymerase chain reaction (PCR). In this study parvovirus B19 presence was assessed by PCR, immunoblot and enzyme-linked immunosorbent assay in sera from children with mainly oncological and hematological diseases. In 45% of sera B19 DNA was observed. Of the children 25% had IgG antibodies to viral protein 1 and 2 (VP1/2) and 15% to nonstructural protein 1 (NS1). In 6% of children IgM antibodies to VP1/2 were detected. These results indicate that the number of children with immune response to B19 proteins is distinctly lower than the number of children with B19 DNA. Transfusions of blood products might have been a possible route for B19 infection. Establishment and maintenance of a persistent parvovirus B19 infection with or without immune response are enhanced in the analyzed immunocompromised children in comparison with immunocompetent children. A persistence of B19 DNA was demonstrated up to 10 months in patients sera.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574901     DOI: 10.1007/s004300050063

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  7 in total

1.  Parvovirus b19 infections and blood counts in blood donors.

Authors:  David Juhl; Dagmar Steppat; Siegfried Görg; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

2.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 3.  Advances in human B19 erythrovirus biology.

Authors:  Annabelle Servant-Delmas; Jean-Jacques Lefrère; Frédéric Morinet; Sylvie Pillet
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

4.  Parvoviruses PARV4/5 in hepatitis C virus-infected patient.

Authors:  Jacqueline F Fryer; Sebastian B Lucas; David Padley; Sally A Baylis
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

5.  Respiratory DNA viruses are undetectable in nasopharyngeal secretions from adenotonsillectomized children.

Authors:  Ronaldo Bragança Martins; Lucas Penna Rocha; Mirela Moreira Prates; Talita Bianca Gagliardi; Balduino Biasoli; Marcelo Junqueira Leite; Guilherme Buzatto; Miguel Angelo Hyppolito; Davi Casale Aragon; Edwin Tamashiro; Fabiana Cardoso Pereira Valera; Eurico Arruda; Wilma Terezinha Anselmo-Lima
Journal:  PLoS One       Date:  2017-03-17       Impact factor: 3.240

6.  Multisystem Involvement Induced by Human Parvovirus B19 Infection in a Non-immunosuppressed Adult: A Case Report.

Authors:  Qihang Zou; Peisong Chen; Jiaxin Chen; Dingbang Chen; Han Xia; Ling Chen; Huiyu Feng; Li Feng
Journal:  Front Med (Lausanne)       Date:  2022-04-12

7.  Distinctive Acellular Lipid Emboli in Hemoglobin SC Disease following Bone Marrow Infarction with Parvovirus Infection.

Authors:  Danielle M Graff; Erin Owen; Robert Bendon; Salvatore Bertolone; Ashok Raj
Journal:  Case Rep Hematol       Date:  2015-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.